# A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer

> **NCT00701558** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 20 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00701558
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-10
- **Final completion:** 2010-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00701558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00701558, "A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00701558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*